NorthSea Therapeutics B.V.
  • Home
  • About
  • Team
  • Presentations
  • Pipeline
  • News
  • Publications
  • Career
    • Job openings
  • Contact
Select Page

NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline

20 Nov 2020 | News

NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development...

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

8 Jan 2020 | News

Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will...

NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

25 Sep 2019 | News

Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases,...

NorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO

4 Sep 2019 | News

Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of...

Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells

9 Nov 2018 | News

Results to be presented at the AASLD congress 2018, 9-13 November In a biopsy-confirmed fibrotic ob/ob NASH mouse model, icosabutate reduced hepatic fibrosis in association with a 45% decrease in myofibroblast content in pre- versus post-treatment liver biopsies In a...

Potential of icosabutate as a novel approach to the treatment of NASH highlighted in late-breaker at The International Liver CongressTM 2018

12 Apr 2018 | News

Late breaker EASL Icosabutate, a structurally engineered fatty acid, displays optimised phamacokinetics for targeting both metabolic and inflammatory pathways in the liver, both with key relevance for NASH Pre-clinical data show broad and powerful pharmacodynamic...
« Older Entries
Next Entries »

NorthSea Therapeutics

NorthSea Therapeutics is a clinical-stage biotech company developing first-in-class, oral, structurally engineered fatty acid therapeutics.

Contact

E: info@northseatherapeutics.com
T: +31 (0) 35 760 65 05

Address

Paasheuvelweg 25-C6
1105 BP Amsterdam
The Netherlands

© NorthSea Therapeutics B.V.